

Traverse Therapeutics, Inc. (TVTX)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001438533

Traverse Therapeutics, Inc. TVTX; healthcare	
Grade	B A B C D E second fifth of 371 graded peers percentile 27.0; sampling error 2.5 points; lower is stronger
Rank	101 of 371
Profitability	B percentile 28.1
Solvency	C percentile 56.2
Growth and financing	B percentile 37.0
Reliability	0.91 AUC filers with \$591M to \$2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$591M to \$2.67B assets total assets \$605.2M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active not computable: distress, fortress balance sheet
Inputs computable	8 of 14
Graded from	filings received through Feb 19, 2026 232 days before the rescans; latest periodic filing 10-Q received Aug 4, 2026
Last close	\$52.05 2026-10-08; market equity \$4.9B
Price used in grade	None



B, the elk
second fifth of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescans
split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: C from Apr 21, 2025, C/D from Jul 21, 2025, C from Aug 21, 2025

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 19, 2026

Those statements in the following discussion that are not historical in nature should be considered forward-looking statements that are inherently uncertain. Actual results and the timing of the events may differ materially from those contained in these forward-looking statements due to a number of factors, including those discussed in the "Cautionary Statement Regarding Forward-Looking Statements" and "Risk Factors" set forth elsewhere in this Annual Report. We are a biopharmaceutical company headquartered in San

Diego, California, focused on identifying, developing and delivering life-changing therapies to people living with rare kidney and metabolic diseases.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 28.1						
Gross profitability		79.4%	32.2%	8.9	372	2025-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(10.6%)	(6.6%)	39.5	811	2025-12-31
Gross margin stability, five years		2.0 pts	2.8 pts	36.0	243	2025-12-31
Solvency, sleeve percentile 56.2						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		(5.38)	(0.31)	53.1	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Current ratio		2.74x	2.96x	59.3	839	2025-12-31
Growth and financing, sleeve percentile 37.0						
Revenue growth, three-year compound		64.9%	10.0%	8.9	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000 pretax income must exceed the validity floor and imply a 0%-100% tax rate
Reinvestment rate		not computable	37.1%			
Asset growth, three years		(3.5%)	2.1%	60.0	704	2025-12-31
Net share issuance, one year		3.9%	2.5%	42.0	634	2026-02-13

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
96	Mirum Pharmaceuticals, Inc. (MIRM)	25.7	B	
97	Phibro Animal Health Corp. (PAHC)	25.9	B	
98	GE HealthCare Technologies Inc. (GEHC)	26.2	B	
99	Sensus Healthcare, Inc. (SRTS)	26.5	B	
100	Lineage Cell Therapeutics, Inc. (LCTX)	26.8	B	
101	Traverse Therapeutics, Inc. (TVTX) <	27.0	B	
102	Tela Bio, Inc. (TELA)	27.3	B	fortress balance sheet
103	Alphatec Holdings, Inc. (ATEC)	27.6	B	
104	Agape ATP Corp. (ATPC)	27.8	B	late filer
105	Agios Pharmaceuticals, Inc. (AGIO)	28.1	B	short runway
106	Myriad Genetics Inc. (MYGN)	28.4	B	fortress balance sheet

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	177.3%	8.0%	95
Distance from 52-week high	(22.9%)	(31.4%)	62
EBIT to enterprise value	(1.3%)	(1.5%)	50
Free cash flow yield	(5.7%)	(1.0%)	39
Book value to price	0.00	0.28	12
Sales to price	0.10	0.31	25
Composite equity issuance, five years	44.8%	20.3%	65
Relative strength against the sector, log excess return	0.81	(0.14)	95

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$117.7M
Operating cash flow, four quarters	\$92.7M
Months of runway	not finite
Days since last periodic filing	66 (10-Q received Aug 4, 2026)

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$490.7M	2025-12-31	2026-02-19	10-K	0001438533-26-000014
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$10.3M	2025-12-31	2026-02-19	10-K	0001438533-26-000014
3	assets	us-gaap:Assets	\$605.2M	2025-12-31	2026-02-19	10-K	0001438533-26-000014
4	net income	us-gaap:NetIncomeLoss	-\$25.5M	2025-12-31	2026-02-19	10-K	0001438533-26-000014
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$37.8M	2025-12-31	2026-02-19	10-K	0001438533-26-000014
6	assets	us-gaap:Assets	\$594.1M	2024-12-31	2026-02-19	10-K	0001438533-26-000014
7	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$233.2M	2024-12-31	2026-02-19	10-K	0001438533-26-000014
8	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$7.7M	2024-12-31	2026-02-19	10-K	0001438533-26-000014
9	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$145.2M	2023-12-31	2026-02-19	10-K	0001438533-26-000014
10	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$11.4M	2023-12-31	2026-02-19	10-K	0001438533-26-000014
11	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$109.5M	2022-12-31	2025-02-21	10-K	0001438533-25-000010
12	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$4.4M	2022-12-31	2025-02-21	10-K	0001438533-25-000010
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$131.8M	2021-12-31	2024-02-20	10-K	0001438533-24-000005
14	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$3.8M	2021-12-31	2024-02-20	10-K	0001438533-24-000005
15	current assets	us-gaap:AssetsCurrent	\$437.6M	2025-12-31	2026-02-19	10-K	0001438533-26-000014
16	current liabilities	us-gaap:LiabilitiesCurrent	\$159.9M	2025-12-31	2026-02-19	10-K	0001438533-26-000014
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$1.5B	2025-12-31	2026-02-19	10-K	0001438533-26-000014
18	operating income	us-gaap:OperatingIncomeLoss	-\$62.8M	2025-12-31	2026-02-19	10-K	0001438533-26-000014
19	book equity	us-gaap:StockholdersEquity	\$114.8M	2025-12-31	2026-02-19	10-K	0001438533-26-000014
20	liabilities	us-gaap:Liabilities	\$490.4M	2025-12-31	2026-02-19	10-K	0001438533-26-000014
21	operating income	us-gaap:OperatingIncomeLoss	-\$388.1M	2023-12-31	2026-02-19	10-K	0001438533-26-000014
22	interest expense	us-gaap:InterestExpense	\$11.3M	2023-12-31	2024-02-20	10-K	0001438533-24-000005
23	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$280.0M	2023-12-31	2026-02-19	10-K	0001438533-26-000014
24	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$668,000	2023-12-31	2024-02-20	10-K	0001438533-24-000005
25	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$186.3M	2022-12-31	2025-02-21	10-K	0001438533-25-000010
26	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$191,000	2022-12-31	2024-02-20	10-K	0001438533-24-000005
27	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$14.8M	2021-12-31	2024-02-20	10-K	0001438533-24-000005
28	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$5.1M	2021-12-31	2024-02-20	10-K	0001438533-24-000005
29	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$42.7M	2020-12-31	2023-02-23	10-K	0001438533-23-000008
30	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$6.8M	2020-12-31	2023-02-23	10-K	0001438533-23-000008
31	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$38.5M	2023-12-31	2026-02-19	10-K	0001438533-26-000014
32	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItems	\$376.1M	2023-12-31	2026-02-19	10-K	0001438533-26-000014
33	income tax	us-gaap:IncomeTaxExpenseBenefit	\$223,000	2023-12-31	2026-02-19	10-K	0001438533-26-000014
34	current assets	us-gaap:AssetsCurrent	\$616.8M	2023-12-31	2025-02-21	10-K	0001438533-25-000010
35	current liabilities	us-gaap:LiabilitiesCurrent	\$177.9M	2023-12-31	2025-02-21	10-K	0001438533-25-000010
36	current assets	us-gaap:AssetsCurrent	\$486.4M	2022-12-31	2024-02-20	10-K	0001438533-24-000005
37	current liabilities	us-gaap:LiabilitiesCurrent	\$142.2M	2022-12-31	2024-02-20	10-K	0001438533-24-000005
38	assets	us-gaap:Assets	\$788.9M	2023-12-31	2025-02-21	10-K	0001438533-25-000010
39	assets	us-gaap:Assets	\$672.6M	2022-12-31	2024-02-20	10-K	0001438533-24-000005
40	shares outstanding	dei:EntityCommonStockSharesOutstanding	92,241,550	2026-02-13	2026-02-19	10-K	0001438533-26-000014
41	shares outstanding	dei:EntityCommonStockSharesOutstanding	88,739,826	2025-02-18	2025-02-21	10-K	0001438533-25-000010